Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Cardiff Oncology and CytomX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| CytomX Therapeutics | -435.21% | -38.46% | -30.33% |
Earnings and Valuation
This table compares Cardiff Oncology and CytomX Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $590,000.00 | 159.54 | -$45.85 million | ($0.60) | -2.02 |
| CytomX Therapeutics | $76.20 million | 9.58 | -$17.37 million | ($0.50) | -6.70 |
CytomX Therapeutics has higher revenue and earnings than Cardiff Oncology. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Cardiff Oncology and CytomX Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 4 | 2 | 0 | 2.14 |
| CytomX Therapeutics | 1 | 1 | 9 | 1 | 2.83 |
Cardiff Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 519.83%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 255.22%. Given Cardiff Oncology’s higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than CytomX Therapeutics.
Volatility and Risk
Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.
Institutional & Insider Ownership
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
CytomX Therapeutics beats Cardiff Oncology on 11 of the 15 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
